-$1.57 EPS Expected for Urogen Pharma Ltd (NASDAQ:URGN) This Quarter

Equities research analysts expect that Urogen Pharma Ltd (NASDAQ:URGN) will announce ($1.57) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Urogen Pharma’s earnings, with estimates ranging from ($1.86) to ($1.20). Urogen Pharma reported earnings per share of ($1.46) during the same quarter last year, which suggests a negative year over year growth rate of 7.5%. The company is scheduled to report its next earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($4.79) per share for the current year, with EPS estimates ranging from ($5.13) to ($4.45). For the next year, analysts expect that the firm will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.41) to ($3.37). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.26) by $0.20.

URGN has been the subject of a number of recent research reports. Stifel Nicolaus set a $41.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Sunday, October 20th. Oppenheimer lowered their price target on shares of Urogen Pharma from $70.00 to $62.00 in a research report on Wednesday. HC Wainwright set a $75.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Monday, October 21st. ValuEngine raised shares of Urogen Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Cowen reissued a “buy” rating on shares of Urogen Pharma in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Urogen Pharma presently has a consensus rating of “Buy” and an average price target of $51.86.

In other Urogen Pharma news, CFO Peter P. Pfreundschuh sold 1,416 shares of Urogen Pharma stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.07, for a total value of $46,827.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of URGN. Tower Research Capital LLC TRC grew its stake in shares of Urogen Pharma by 1,500.0% in the third quarter. Tower Research Capital LLC TRC now owns 2,000 shares of the company’s stock worth $47,000 after acquiring an additional 1,875 shares during the period. SG Americas Securities LLC purchased a new position in Urogen Pharma during the third quarter valued at approximately $1,186,000. Parallel Advisors LLC purchased a new position in Urogen Pharma during the third quarter valued at approximately $36,000. Bank Hapoalim BM lifted its holdings in Urogen Pharma by 4.9% during the third quarter. Bank Hapoalim BM now owns 27,230 shares of the company’s stock valued at $653,000 after purchasing an additional 1,260 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Urogen Pharma by 28.5% during the third quarter. California Public Employees Retirement System now owns 19,400 shares of the company’s stock valued at $462,000 after purchasing an additional 4,300 shares in the last quarter. 70.33% of the stock is owned by institutional investors and hedge funds.

Shares of URGN stock traded up $0.27 on Friday, hitting $26.57. 104,200 shares of the company’s stock traded hands, compared to its average volume of 165,714. Urogen Pharma has a one year low of $20.72 and a one year high of $55.49. The stock has a market capitalization of $549.59 million, a price-to-earnings ratio of -5.54 and a beta of 1.12. The company’s fifty day simple moving average is $22.96 and its 200 day simple moving average is $31.61.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.